Survivin as a therapeutic target for neuroendocrine neoplasms.
Hane Y, Tsuchikawa T, Nakamura T, Hatanaka KC, Sasaki K, Kawai N, Takeuchi S, Tanaka K, Nakanishi Y, Asano T, Noji T, Shichinohe T, Hatanaka Y, Hirohshi Y, Torigoe T, Hirano S.
Hane Y, et al.
Neuroendocrinology. 2025 Jan 2:1-31. doi: 10.1159/000543270. Online ahead of print.
Neuroendocrinology. 2025.
PMID: 39746333